President of Health 2.0 Advisors (the market intelligence branch of the Health 2.0 Empire) Marco Smit will give an overview of the changes in pharma from the digital technology perspective. Marco has been a heading up the Health 2.0 market intelligence business unit, which helps pharma companies with their growth / innovation needs, and previously worked with pharma companies as consultant (e.g. Genentech) and executive in partner companies (e.g. Affymetrix).
Innovations in Adherence
For patients, improving medication adherence can both bolster patients’ health as well as revenues. But pharma can’t help realize this objective on its own: adherence is a multi-stakeholder sport. Many of the innovations for adherence improvement are coming from outside of pharma...and sometimes aim to help payers (employers, insurance companies) or others whose incentives are not aligned with those of pharma companies
Clinical Trial Recruitment and Clinical Research Innovation
Phase III clinical trials typically represent 50-90 % of the cost of developing an individual drug, and their costs are rising fast. The FDA is also becoming more demanding post-approval for evidence that drugs are safe and provide clinical benefit. How can digital communications and patient engagement tools speed recruitment and improve trial outcomes? And how are the pioneering companies pushing the boundaries of what is possible and what gets done?